Ads
related to: CBAY- Learn How To Trade
We can help you invest with speed
& accuracy at every step of a trade
- Open an Account
Choose The Account That Works
Best For You, and Start Investing
- Trade
Buy, sell, track the market.
Discover our investment products.
- Ranked #1 in Research
Kiplinger's Best Online Brokers
Annual Review from August 31, 2023
- Learn How To Trade
Search results
Assenagon Asset Management S.A. Invests $17.63 Million in CymaBay Therapeutics, Inc. (NASDAQ:CBAY)
ETF DAILY NEWS· 14 hours agoAssenagon Asset Management S.A. purchased a new position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) during the fourth quarter, according to the company ...
CymaBay Therapeutics (NASDAQ:CBAY) Receives New Coverage from Analysts at StockNews.com
ETF DAILY NEWS· 3 days agoThe firm issued a sell rating on the biopharmaceutical company’s stock. William Blair cut shares of CymaBay Therapeutics from an outperform rating to a market perform rating in a report on Monday ...
Cymabay Therapeutics Inc [CBAY] stock for 191,849 USD was sold by Dorling Janet – Knox Daily
Knox Daily· 7 days agoAs published in a research note from Raymond James on February 13, 2024, Cymabay Therapeutics Inc [CBAY] has been rated down from an Outperform to a Mkt perform. Over the ...
Gilead reduces 2024 earnings guidance after completing CymaBay takeover By Investing.com
Investing.com· 6 days agoGilead reduces 2024 earnings guidance after completing CymaBay takeover
Gilead finalizes CymaBay acquisition to bolster liver disease treatments By Investing.com
Investing.com· 6 days agoGilead finalizes CymaBay acquisition to bolster liver disease treatments
Gilead completes CymaBay acquisition but negative impact on 2024 EPS (NASDAQ:GILD)
Seeking Alpha· 6 days agoGilead Sciences completes $4.3B acquisition of CymaBay Therapeutics, but the transaction will reduce...
Gilead Sciences Announces Completion of Acquisition of CymaBay
Morningstar· 6 days agoGilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for approximately ...
GILD- A Biotech Focused on Boosting Oncology Treatment Reach
MoneyShow via Yahoo Finance· 3 days agoThe EVP of the Kite subsidiary at Gilead Sciences Inc. (GILD) recently presented at the Leerink Partners Global Biopharma Conference. She said the CAR-T industry only has a 15% to 17% share ...